Astellas Pharma Inc. and Seattle Genetics Inc. announced data from the first cohort of a pivotal phase II clinical trial known as EV-201 demonstrated the investigational agent enfortumab vedotin rapidly shrank tumors in most patients, resulting in an objective response rate of 44% (55/125; 95% Confidence Interval: 35.1-53.2).
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
